Replay available

Aethlon Medical (NASDAQ:AEMD) Q3 2020 Earnings Call

Aethlon Medical (NASDAQ:AEMD) Q3 2020 earnings call, held 2020-02-10. Watch the replay and read the transcript on 6ix.

Mon, February 10, 2020 at 4:30 PMendedReplay
Aethlon Medical (NASDAQ:AEMD) Q3 2020 Earnings Call
Company
Aethlon Medical, Inc. (NASDAQ:AEMD)
Period
Q3 2020 earnings call
Date
Mon, Feb 10, 2020, 4:30 PM ET
Replay
Watch the replay on this page · 39 min

On 6ix: 6ix.com/event/aethlon-medical-inc-aemd-q3-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Good day and welcome to the Athlon Medical Third Quarter Fiscal 2020 Earnings and Corporate Update. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Jim Frakes, Chief Financial Officer. Please go ahead.

0:37 Thank you, operator, and good afternoon, everyone. Welcome to Athlon Medical's third quarter 2020 earnings conference call. My name is Jim Frakes, and I am Athlon's Chief Financial Officer. At 4.15 p.m. Eastern time today, Athlon Medical released financial results for its third quarter-ended earnings December 31, 2019. If you have not seen or received Athlon Medical's earnings release, please visit the investors page at www.athlonmedical.com. Following this introduction and the reading of our forward-looking statement, Athlon CEO, Dr. Tim Rodell, and our chairman, Dr. Chuck Fisher, will provide an overview of Athlon's strategy and recent developments.

1:25 I will then make some brief remarks on Athlon's financials. We will then open up the call for the Q&A session. Before I hand the call over to Dr. Rodel, please note that the news released today and this call contain forward-looking statements within the meaning of the Federal Securities Act of 1933 and the Securities Exchange Act of 1934. The company cautions you that any statement that is not a statement of historical fact is a forward-looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements.

2:13 Factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption risk factors in the company's annual report on Form 10-K, for the fiscal year ended March 31, 2019, and in the company's other filings with the Securities and Exchange Commission. Except this may be required by law, the company does not intend nor does it undertake any duty to update this information to reflect future events or circumstances. With that, I will now turn the call over to Dr. Tim Rodell, Athlon Medical's CEO.

2:49 Thank you, Jim, and thank you all for dialing into I'd like first to briefly address the suspension of trading the company's shares by the Securities and Exchange Commission on Friday. We will then update on the progress of our programs in oncology and we'll then discuss our view of the evolving coronavirus outbreak and the potential relevance of the hemopurifier in this and future viral epidemics. As you know, on February 7th, the Securities and Exchange Commission issued an order of suspension of trading, temporarily suspending trading in Athlon Medical, Inc., stock for a period of 10 days.

3:37 The SEC order stated that the suspension was due to concerns regarding the accuracy and adequacy of information in the marketplace that appeared to be disseminated by third-party promoters and recent and unusual market activity since at least January 22nd Athlon is aware that certain third-party promoters may have made claims about the potential efficacy of its products with respect to the coronavirus. The company neither solicited, had advanced knowledge of, nor played any role in the preparation of such reports. Now, I wanted to get that out of the way first so that we can concentrate on what we and our shareholders really care about, which is a discussion of our R&D programs.

4:25 So let me move to that. We are continuing the advancement of the hemopurifier for advanced cancers under our recently approved IDE and breakthrough designation. As we previously disclosed, the initial clinical trial on cancer, known as an early feasibility study, which is the device equivalent of a phase one trial, will be a small single center for the open-label trial in 10 to 12 patients with advanced and or metastatic swing cell carcinoma of the head and neck or head and neck cancer who are receiving pembrolizumab, which is Mark's drug, also known as Keytruda, in the frontline setting for which it received FDA approval last year.

5:11 The protocol for this trial is undergoing IRB and related review. We will be in a position to discuss additional details regarding the trial at that time. To our subsidiary, Exosome Sciences, we are also continuing our collaboration with the Hoag Hospital Group in Newport Beach, California, to characterize diagnostic and prognostic exosomal markers in patients with and at high risk for solid tumors. Additionally, we're also continuing our work under the recently awarded approximately $1.8 million National Cancer Institute contract to develop our benchtop version of the hemopurifier for the isolation and characterization of exosomes.

6:03 These are our major activities in the oncology space. We continue to work on other potential applications and ways that we can investigate the hemopurifier. And now I'd like to move on and discuss our work in the development of the hemocurifier for viral infections, which is an area that remains a major focus of the company and has received a great deal of attention in the context of the current coronavirus outbreak. As you know, in addition to the oncology breakthrough designation, the company has also received a breakthrough designation for the hemocurifier for the treatment of life-threatening viruses that are not addressed with approved therapy. a designation that would generically appear to fit the current coronavirus outbreak, which is now designated as 2019-MCOV.

6:56 That's a working name for this particular coronavirus. It will probably get a different name at some point in the near future. However, in order for the hemoperifier to be evaluated and deployed in this situation, a number of conditions would have to be met, as I will discuss in a minute. and this is the reason we haven't publicly commented before this morning. There is not adequate information out there yet for us to be able to say one way or another whether the hemopurifier is potentially a candidate for the treatment of this disease. But before I go into that, let me step back and provide a quick overview of the status of the current outbreak because a number of the characteristics of this virus that we understand now have a direct impact on the potential for the hemopurifier to intervene in this disease.

7:53 Based on data from the World Health Organization from yesterday morning, there have been a total of 37,558 confirmed infections with this particular strain of the coronavirus. because, as you will see, the majority of these cases are mild disease, and the majority of them, in fact, are in China, where healthcare resources are very strained at this point. Many cases are not yet reported. Many patients who are probably infected can't even get in to see a healthcare practitioner. So the overall figure is probably substantially higher than the reported confirmed number of cases.

8:41 As I've said, The majority of these cases are in China. So out of the 3,700,558 confirmed cases globally, 37,251 of those cases are in China. Of those, 6,000 are defined as severe, which means a 17% rate of severity. And the case fatality rate is 2%. Now, given that the total number of cases is probably higher than what's reported, this case fatality rate may actually be lower than that, more on the order of 1%. Now, as of yesterday, the World Health Organization had reported 812 deaths in China and one death outside of China.

9:38 based on data that are now becoming available today, the mortality rate is probably now closer to 1,000. Of note, as reported yesterday, even with this low case fatality rate, that is the percentage of patients who are infected who die, the total number of deaths in this outbreak has now surpassed the SARS outbreak. So the SARS outbreak affected a smaller number of patients. with a higher fatality rate, but because of the greater number of patients who are infected with this current coronavirus, the mortality rate, even though our percentage basis is lower, has now surpassed the SARS epidemic. Now, for perspective, I have to say that both of these outbreaks, the SARS outbreak and the current coronavirus outbreak, pale in significance.

10:33 Next to influenza, which is a much larger problem that people tend to ignore, for which the CDC, the Centers for Disease Control, estimates that so far this season, in the United States alone, there have been 22 million cases, 210,000 hospitalizations, and 12,000 deaths. This is for a disease Now, to return to the coronavirus, the current coronavirus infection, the causative virus has been identified, it's been sequenced, and as I mentioned, has been designated 2019 NCOV. It's a member of one of the four coronavirus families, the so-called beta family.

11:22 It also includes the SARS virus and the Middle Eastern Respiratory Syndrome, or MERS viruses. which are also in the coronavirus family. But as you can see from the above figures, this virus appears to be much more widespread than those outbreaks, but substantially less dangerous in terms of mortality. Now, as you may know, both Chuck and I have many years of experience in the area of viral disease and viral product development in a number of different academic and commercial settings, and I'm going to ask Chuck to comment briefly in a minute but before I do, let me say that we've been basically tuned into this since the very early days.

12:07 We've been closely monitoring the situation. We've been speaking with our colleagues who may be involved in the care of these patients ultimately, and we've been evaluating whether the hemopurifier could offer any benefit to severely affected patients. Fortunately, as noted above, the majority of patients today have not had severe disease. In fact, The coronavirus is closely related to viruses that cause diseases that are generally referred to as the common cold. So the majority of patients are not severely infected. They're not severely affected. And those with mild disease would never be candidates for treatment with the hemopurifier because it is an extracorporeal device. It involves taking the blood out of the patient, filtering it through the hemopurifier, and then returning it to the patient.

12:56 which obviously is an invasive treatment that would only be appropriate for use in life-threatening situations. Moreover, it were ultimately to be used in any outbreak such as the current one, it would almost certainly not be an initial frontline treatment. In addition, beyond appropriate severity of disease, two additional considerations would have to be satisfied for the hemopurifier to be considered for evaluation and deployment here. First, while the company has previously evaluated the ability of benchtop versions of the hemopurifier to bind multiple viruses, including one other member of the coronavirus family I mentioned previously, the MERS virus, the currently circulating 2019N coronavirus is not yet widely available for evaluation, and therefore the company does not have data showing whether the hemopurifier could clear it. It seems likely that it could, based on the data that we currently have, but unless we have direct data showing that the hemopurifier could bind it, that would be a necessary, although not sufficient, precedent for us to deploy it.

14:08 Second, and potentially at least as important, it's unclear at this time whether a virus that primarily affects the upper respiratory tract, generating pneumonia, such as this one, would in fact be ameliorated by clearance from the circulating blood as the hemopurifier is designed to do. Remember, the hemopurifier is not directed at the lungs. It's directed at the bloodstream. And while this virus almost certainly circulates, it's totally unclear whether clearing it from the circulation would have an impact on the pneumonia that ultimately disables and potentially kills patients. Finally, as noted above, this outbreak is still largely in China, and I think is likely to remain there, and virtually all of the mortality is in China.

14:58 So any use of the hemoperifier in appropriate patients would, based on what we know today, would be focused in China, and would additionally require the support of the Chinese regulatory authorities, not the FDA. With all of these considerations in mind, we intend to monitor the current situation and also the inevitable future outbreaks to come. I think we all understand now that this type of virus is not going to be an isolated case. We've already seen two other deadly coronaviruses, the SARS coronavirus and the MERS coronavirus. We're likely to see additional outbreaks of other coronaviruses and many other viruses as time passes.

15:43 And we're going to deal with these in the same way. We will monitor them. We will look for opportunities to identify situations where the hemopurifier could be beneficial and intervene as appropriate. So let me stop there and ask Chuck Fisher, our chairman, and a close colleague of mine to add any comments he may have before we go on to the next part of the call.

16:09 Chuck? Yes. Thank you, Tim, and thanks, everybody, for joining the call today. I think Tim did a nice job of summarizing The key events, the issue for us to deploy the human purifier at this point would be to demonstrate that we bind the 2019 in COV version of the virus, the one that's in China and is spreading throughout the world. And two, based on what we're seeing, the intensity and severity of that is quite much larger in China than it is anywhere else. And as Tim pointed out, Steven LaRosa, James Frakes, Steven LaRosa, James Frakes on the larger issues of what the company is doing.

17:18 We're tracking very well and I'm very pleased with the overall performance of the team and of all of our programs. Back to you, Tim.

17:29 Thank you, Chuck. So we'll take questions at the end, but what I'd like to do now is turn the call back over to Jim Frakes, our Chief Financial Officer, to report on the financial part of the quarter.

17:46 Thank you, Tim, and good afternoon again, everyone. Our net loss was approximately $820,000, or 28 cents per share, when the third quarter ended December 31, 2019, compared to a net loss of approximately $2 million, or $1.67 per share, when the quarter ended December 31, 2018. We recorded Government contract revenue of approximately $413,000 in the three months ended December 31, 2019. This revenue resulted from work performed under our Phase II melanoma cancer contract with the NCI. We do not record any government contract revenue in the three months ended December 31, 2018.

18:34 Our consolidated operating expenses for the three months ended December 31, 2019 were approximately $1.29 million in comparison with $1.96 million for the three months ended December 31, 2018. This was a decrease of approximately $670,000 or 34% in 2019. And the decrease was due to a decrease in payroll and related expenses of approximately $755,000 which was partially offset by increases in professional fees of approximately $23,000 and in general and administrative expenses of approximately $58,000.

19:20 The $755,000 decrease in payroll and related expenses was due to the combination of a $513,000 reduction in our cash-based compensation expense and a $242,000 decrease in stock-based compensation. The reduction in cash-based compensation expense was due to recording a $506,000 accrual in the December 2018 period related to contractually agreed severance payments for former CEO and former President with no comparable expense in the December 2019 period. The $23,000 increase in our professional fees in 2019 was primarily due to a $101,000 increase in our legal fees and a $27,000 increase in our accounting fees, which were partially offset by a $104,000 decrease in scientific consulting expenses.

20:18 The increase in legal and accounting fees related to increased activity in our registration statement filings and in intellectual property actions, among other matters. The $58,000 increase in general and administrative expense in 2019 was primarily due to the combination of a $29,000 increase in our clinical trial expenses and an $18,000 increase in licenses and permitting costs. Other income or expense during the three months ended December 31, 2019 consisted of interest expense and a gain on share for warrant exchanges. And during the three months ended December 31, 2018 consisted of interest expense only.

21:03 Other income for the three months ended December 31, 2019 was approximately $55,000 in comparison with other expense of approximately $55,000 for the three months ended December 31, 2018. Now, at December 31, 2019, we had a cash balance of approximately $4.1 million. Subsequent to December 31, 2019, we conducted a registered direct offering of approximately 1.9 million shares of common stock at a purchase price of $2 per share or aggregate gross proceeds of approximately $3.77 million before deducting fees payable to the investment bank and other estimated offering expenses payable by us.

21:51 In a concurrent private placement, we also entered into a securities purchase agreement with certain institutional investors pursuant to which we agreed to sell an issue to the purchasers to purchase up to an aggregate of 943,000 shares of our common stock at an exercise price of $2.75 per share. And those warrants carry a term of five and one-half years. Also subsequent to December 31, 2019, investors that participated in our December 2019 public offering exercised outstanding warrants to purchase an aggregate of approximately 2.6 million shares of our common stock were aggregate cash proceeds to us of approximately $3.89 million of court expenses.

22:39 The combination of the gross proceeds from the registered direct offering from the warrant exercises amounted to approximately $7.66 million in gross proceeds to the company subsequent to December 31, 2019. We included these earnings and related commentary in a press release earlier this afternoon. That release included the balance sheet for December 31, 2019 and the statements of operations for the three and nine-month periods ended December 31, 2019 and 2018. And we will file our quarterly report on Form 10-Q following this call. Our next earnings call will coincide with the filing of our annual report on Form 10-K in June.

23:26 And now Chuck, Tim, and I would be happy to take any questions that you may have. Operator, please open the call for questions. If we could just start with the cancer feasibility study program. Is there anything else that you can talk about relative to where you are, what you need, I guess, before you can go ahead to the next steps, which I guess is to start the study?

24:18 So any other details that you can give us and anything in terms of when you think that the timeline might be for starting that study?

24:29 Yeah, terrific. Thanks, Brian. This is Tim Rodell, and thanks for the question. As you know, in any clinical trial, you need approval. Once the FDA has authorized the trial, you need approval from at least one local review group, which is the Institutional Review Board, but in major cases, Thank you. Thank you. Thank you. the IRB and be ready to start the trial. You know, I would say shortly, I think sometime around the end of the first quarter may be a reasonable prediction, but that could change.

25:35 Okay. Thanks, Tim. And is it fair to assume that if you can start on the timeline that you just mentioned that you believe it would be finished by the end of The current calendar year, so by the end of 2020?

25:57 Well, I would love to give you a firm answer to that, but as you know, that would probably be pretty dangerous for me to do. Until we actually open the trial and start to see the enrollment rates, it's very hard to predict exactly how fast they're going to go. This is a small trial, 10 to 12 patients, so we don't need that many and this is a very busy center that we're going to be working in with a very large head and neck patient population. So I'm hopeful that the time frame you talk about is realistic, but I'm really not going to be in a position to say anything much more than that until we see. Even if you already know exactly what the number of patients that are being taken care of in the center is, you still don't know what percentage of those patients are going to get consented for a trial like this. So, you know, I'm hopeful that that's a reasonable estimate, but I'll be more comfortable giving you something a little bit more precise once we get open and see a couple months of enrollment.

27:04 Okay. Great. Relative to the coronavirus, I know it's early. Nobody has a whole lot of answers, so I certainly don't expect Thank you for having me.

27:43 It's really basically the issues that Chuck and I talked about. I think that given the data that we have with a lot of other viruses, including, as I said, one additional coronavirus, the MERS virus, it appears that the chemo purifier has very broad activity against all glycosylated viruses that affect humans, but it would be unethical for us to enter into any kind of treatment without knowing specifically that this virus is bound to the hemopurifier. So that's a data point that we need. I think the bigger question is, you know, our experience in treating viruses, and as you know, we do have fairly extensive human clinical experience, is with viruses where the primary mode of pathology, if you will, involves a circulation.

28:38 Hepatitis C virus circulates and if you decrease the amount of circulating hepatitis C, patients do better. We know that. We're not in the business of treating hepatitis C anymore simply because it's a disease that can be treated with drugs now rather than an invasive treatment like the hemopurifier. But probably a much more relevant example is a single patient we treated with Ebola. And we do know with Ebola virus and probably with all of the other hemorrhaging fever viruses like Barberg agent, like Hanna virus here in the United States. These viruses circulate in very, very high titers and the amount of circulating virus appears to be directly related to the outcome of the disease, how the patients do.

29:30 You know, in a situation like an Ebola patient that we treated, we were able to see that we cleared huge quantities of the virus, captured them in the hemopurifier, and the patient did better. The situation here is a bit different from that, and I'm not saying that to predict what the outcome would be one way or another, but the coronavirus we know is transmitted through the lungs. That is, it's inhaled or it's picked up from mucous membranes. So it doesn't enter... through the bloodstream, and its primary target is the lung. Patients get pneumonia, and ultimately, they're presumably dying of respiratory failure. Now, some of those patients are probably in shock as well. We just don't have enough data on the fatal cases at this point to be able to say.

30:16 So it's not a slam dunk that clearing circulating virus would have an impact on what's really hurting these patients, which is the damage in their lungs. So, you know, that's similar to basically what I've already said. We don't know enough yet at this point. If the answer to both of those questions is yes, we could bind the virus and patients have a lot of circulating virus that may have an impact on the outcome of their lung disease, then I would say it could potentially have a role there. Tim, just for a little clarity on kind of where you are in terms of sort of the next steps, I guess. Is it to talk to Chinese authorities?

31:05 Maybe you've already done that. I don't know. But do you have sort of a specific game plan, sequential steps that you need to go through that you think will answer the questions that you have relative to about whether hemopurification has applicability against coronavirus. Sure.

31:27 You know, I think the two things that we definitely would need, as I said, the two things we need to know are can we bind it, and that's an experiment that we're not in a position to do now, but we're going to keep our eyes open for a way that we could do that. As you know, this is a dangerous virus and has to be evaluated in high-level hospitals Biosecurity Facilities, the kind of facilities that are used to handle all life-threatening viruses. So we would need to identify, we will need to identify a place where that can happen, and we will need access to the virus. Beyond that, I think that we're going to need to understand more about what levels the virus circulates at and begin to put together a story that we can take to and say, we actually think that this could work here.

32:21 So it's a bit of a sequential story. I can't give you an exact time frame for how that could happen, but that's the process. What I will say is that the dissemination of information about this virus and about this outbreak is stunningly current. The New England Journal opened up essentially an ongoing edition where they're turning around publications, case reports, and case series literally on a daily basis. All of the other major medical journals are publishing very quickly. So we are learning a lot about how these patients get infected, how the virus is transmitted, and ultimately how the patients who do succumb die.

33:08 So I think we're going to have a much better idea of what the actual course of the disease is The other thing we're going to have an idea of is what the course is likely to be for this particular outbreak. That is, is it slowly becoming contained? The rate at which it is expanding outside China is encouragingly slow and limited at this point, but whether China has peaked or not, I don't think we know. We'll understand that better over the course of the next few weeks. Chuck, do you want to add anything to that?

33:49 Yeah, thanks, Tim. I think you captured the key points. The issue is to recognize we bind what's circulating. And if you intuit from this from other diseases, whether it's Ebola or Marburg or the flu of 1918, et cetera, many of them had a respiratory component but the key thing in each one of them is they had high levels of circulating titers, as Tim has mentioned. If we're able to demonstrate that we in fact bind the virus, which is not an unreasonable assumption since we have bound other coronaviruses, it's possible. And two, if there's an association between circulating viral titers in the blood with the severity of the pulmonary disease, then I think that's a case that makes it possible Thank you very much.

35:11 They're on essentially a 24-7,365 program now, and we're seeing some of their physicians and health care providers die. That tells me that in a concentrated environment that the severity is much worse. If we capture people and get them isolated, perhaps they're able to clear. We don't know if there's something in that juxtaposition that raises the mortality in that setting. Those are all questions I think all of us, who study these kinds of fields are very much looking at. And whether you look at the WHO or any of the surveillance organizations, they're all saying fundamentally the same thing. Tim? I appreciate that very much. I'll detail.

35:57 Just one last one relative to the Chinese and getting access to the virus. Have Do you have a communication with the Chinese directly? And the other part of that is, do you have a kind of a game plan or some sort of insight into when or if you'd be able to get access to samples?

36:23 Thanks for that, and they're both good questions. First of all, The viruses, once they're identified, tend to become available to researchers reasonably quickly, and we were actually able to evaluate the MERS virus fairly early in that epidemic. So I would say we would expect that it would become available to researchers in the reasonably near future. I don't want to say in terms of days or weeks. I won't comment. on any contact with Chinese regulatory authorities. I don't think that would be appropriate. What I would say is that it is our understanding that the Chinese are doing the same thing that all regulators are doing, which is making sure that potentially helpful things can get deployed and into use as quickly as possible.

37:28 But I'm not going to comment on our... on any contact we may or may not have had with the Chinese regulators. What I will say is that for us to have a meaningful conversation with any regulatory authority would require us to have an understanding of the two major issues that we've been talking about. Okay, great. I appreciate it. Thanks, guys. This will conclude our question and answer session. I would like to turn the conference back over to Dr. Rodell for any closing remarks.

38:06 Yeah, I'd just again like to thank everybody for calling in and for your continuing interest. We intend to be as forthcoming as we possibly can with respect to all of the issues that we've discussed. So when we have something meaningful and material to say, we plan to get it out as quickly as possible. Thanks again and have a good afternoon. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Follow Aethlon Medical, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Dr. Chuck Fisher

Chairman

Jim Frakes

Chief Financial Officer

Dr. Tim Rodell

Chief Executive Officer

More from Aethlon Medical, Inc.